CASE COMMENTS: NATIONAL CASE LAW – ANTITRUST – UNITED STATES – MOTION TO DISMISS – TACTICS TO DELAY THE APPROVAL OF GENERICS

Antitrust – United States – Tactics to delay the approval of generics: A Federal Court refuses to dismiss an antitrust case against a pharmaceutical company (GlaxoSmithKline)

KEYWORDS

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In re Flonase Antitrust Litigation: United States District Court for the Eastern District of Pennsylvania, Case no. 2:08-CV-3301, June 2, 2011, "GlaxoSmithKline" On June 2, 2011, the U.S. District Court for the Eastern District of Pennsylvania

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

Quotation

Jean-Christophe Roda, Antitrust – United States – Tactics to delay the approval of generics: A Federal Court refuses to dismiss an antitrust case against a pharmaceutical company (GlaxoSmithKline), 2 June 2011, Concurrences N° 4-2011, Art. N° 40092, p. 215

Visites 463

All reviews